Topical 10% tranexamic acid for erythematotelangiectatic steroid-induced rosacea

Jakhar, Deepak; Kaur, Ishmeet; Misri, Rachita

doi:10.1016/j.jaad.2019.12.067

Cited by 13 publications

(17 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, there were notable decreases in the visual analog scale scores for itching, flushing, and burning, and no significant adverse events were observed [39]. Topical tranexamic acid was also used to treat erythematotelangiectatic rosacea in two other studies (with 20 patients and 1 patient, respectively), with the results of both studies implying promising therapeutic effects with a good safety profile [40,41].…”

Section: Topical Therapiesmentioning

confidence: 99%

Rosacea Treatment: Review and Update

Zhang

Tang

Wang

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Rosacea is a chronic and inflammatory skin disease characterized by flushing, nontransient erythema, papules/pustules, telangiectasia, and phymatous changes. Secondary manifestations, such as itching, burning, or stinging, are often observed in patients with rosacea. In 2017, a phenotype-based approach for diagnosis and classification was recommended. With the update of the diagnosis and classification of rosacea, treatment options for patients with rosacea have attracted the attention of dermatologists. Here, we summarize the latest advances in rosacea treatment, including skin care and cosmetic treatments, topical therapies, oral therapies, laser- and light-based therapies, injection therapies, treatments for specific types of rosacea, treatments for systemic comorbidities, and combination therapies. The impact of the phenotype-based approach on rosacea treatment and future directions are also discussed.

show abstract

Section: Topical Therapiesmentioning

confidence: 99%

Rosacea Treatment: Review and Update

Zhang

Tang

Wang

et al. 2020

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…TA side effects may also be avoided by using it against skin cancers via topical administration or against other surfaceaccessible malignancies such as superficial bladder cancers (Javadpour 1989) or lung tumors (Moghissi et al, 2004;Jang et al, 2006). Although a 1% (w/v) TA concentration is 64 mM, this concentration is in line with established topical or intradermal concentrations administered for bleeding reduction (0.7%, (Ker et al, 2013)), melasma (3%, (Ebrahimi and Naeini 2014)), or rosacea (5-10%, (Jakhar et al, 2020;Daadaa et al, 2021)). In addition, it has been well established that topically administered TA has less than 10% of the systemic impact of a similar dose delivered intravenously (Ker et al, 2013;Ausen et al, 2019).…”

Section: Discussionmentioning

confidence: 95%

Repurposing Tranexamic Acid as an Anticancer Agent

et al. 2022

View full text Add to dashboard Cite

Tranexamic Acid (TA) is a clinically used antifibrinolytic agent that acts as a Lys mimetic to block binding of Plasminogen with Plasminogen activators, preventing conversion of Plasminogen to its proteolytically activated form, Plasmin. Previous studies suggested that TA may exhibit anticancer activity by blockade of extracellular Plasmin formation. Plasmin-mediated cleavage of the CDCP1 protein may increase its oncogenic functions through several downstream pathways. Results presented herein demonstrate that TA blocks Plasmin-mediated excision of the extracellular domain of the oncoprotein CDCP1. In vitro studies indicate that TA reduces the viability of a broad array of human and murine cancer cell lines, and breast tumor growth studies demonstrate that TA reduces cancer growth in vivo. Based on the ability of TA to mimic Lys and Arg, we hypothesized that TA may perturb multiple processes that involve Lys/Arg-rich protein sequences, and that TA may alter intracellular signaling pathways in addition to blocking extracellular Plasmin production. Indeed, TA-mediated suppression of tumor cell viability is associated with multiple biochemical actions, including inhibition of protein synthesis, reduced activating phosphorylation of STAT3 and S6K1, decreased expression of the MYC oncoprotein, and suppression of Lys acetylation. Further, TA inhibited uptake of Lys and Arg by cancer cells. These findings suggest that TA or TA analogs may serve as lead compounds and inspire the production of new classes of anticancer agents that function by mimicking Lys and Arg.

show abstract

“…[5][6][7] Recently, several studies have shown its benefit against rosacea according to the anti-inflammatory effect of TXA. 8,9,11,12 Some parts of the pathogeneses of rosacea are similar to acne. Currently, studies regarding TXA in acne have not been conducted before.…”

Section: Discussionmentioning

confidence: 99%

Adjunctive treatment for acne vulgaris by tranexamic acid

Charoenwattanayothin

Saiwichai

Chaichalotornkul

2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Acne is a common problem in dermatologic clinics. The pathogenesis of acne involves various factors, such as increased sebum production and alteration of the quality of sebum lipids caused by increased androgen activity, abnormal keratinization of the infundibular epithelium, colonization of Propionibacterium acnes (P. acnes) within the follicles, and the inflammation process. 1 P. acnes may stimulate sebaceous glands via the toll-like receptors (TLRs), mainly TLR2.Keratinocytes and monocytes in acne lesions also express TLR2 on the surface. The TLR2-dependent pathway activation leads to a triggering of the nuclear transcription factor and then produces multiple cytokines and chemokines such as IL-1, IL-8, IL-12, and TNFα. 2 Furthermore, P. acnes can release various exogenous proteases by activating the protease-activated receptor-2 or PAR-2 on the keratinocyte surface. These proteases can enhance the transcription of pro-inflammatory cytokines, for instance IL-1a, IL-8, TNFα, and a variety of matrix metalloproteinases. 1 Currently, numerous treatment options are available, but acne remains a chronic inflammatory disease. Concerning adverse effects of conventional medicines, alternative medications with antiinflammatory effects have increased in popularity. 3

show abstract

Topical 10% tranexamic acid for erythematotelangiectatic steroid-induced rosacea

Cited by 13 publications

References 3 publications

Rosacea Treatment: Review and Update

Rosacea Treatment: Review and Update

Repurposing Tranexamic Acid as an Anticancer Agent

Adjunctive treatment for acne vulgaris by tranexamic acid

Contact Info

Product

Resources

About